Oncolinx (Boston, MA) is developing the next generation of antibody-drug conjugates (ADCs)–powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment.

Website : https://www.oncolinx.com/

Call 2020

The 2020 Call for Application is now close. Stay tuned for the 2021 Call



Receive notifications about the YEi Start in France program (Call for applications, announcement of the laureates, YEi events, etc.)

Social Links